Dear All, I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City NY! The deadline to
Dear All, Heads up! Having just yesterday announced funding of its 100th project, CARB-X have today announced two funding rounds for 2024. With application dates of 18-29 Mar 2024 and 23 Sep-4 Oct 2024, applications are sought on 4 major areas (see extended details below my signature): Therapeutics for Infections Caused by Gram-Negative Pathogens (WHO and
Update on 11 October 2023: The annual BARDA Industry Day is 13-14 November 2023! You can attend virtually or in person at the Grand Hyatt Washington, DC. Click here for more details! Dear All, Hot on the heels of the BAA from BARDA and from ARPA-H, we now have a Broad Agency Announcement from the FDA! There
Dear All (and with thanks to Kevin for co-authoring), The UK NHS England Pilot is known to us all as the first real attempt at an antibiotic subscription model and now it will be undergoing a major overhaul. In case you are a new reader or would like a refresher on the pilot, here are the links
Dear All, Two items for your attention today: an immediate action for you to take to support PASTEUR plus a launch event for a major Wellcome Trust project for your calendar. First, as you may recall, the Oversights & Investigations Subcommittee of the US House Energy & Commerce Committee recently held a hearing about the impact of AMR.
Dear All, Greetings from ECCMID 2023 in Copenhagen! The days are busy, but last night we had a joint session between ECCMID and the Global Leaders Group on Antimicrobial Resistance (GLG) entitled “Forging partnerships between science and policy: A high-level Antimicrobial Resistance (AMR) event” had an excellent scientific program focused on prevention and use of diagnostics, but
Dear All, Following hard on the heels of the very successful call for signatories of a letter in support of PASTEUR (2 Mar 2023 newsletter; copy of final signed letter with > 230 signatories!), we now have two more calls for letters supporting key AMR funding initiatives. And importantly, you do not have to be
Dear All, A key theme of all discussions on Pull incentives is that substantial rewards should go only to molecules with high medical value. We’re still learning to define the idea of high value and today’s newsletter brings together 3 threads that feed into this conversation: First, we have the idea a priority pathogen list.
Dear All, A short one today! Please peruse both the funding opportunities and upcoming meetings just below my signature. Of special note: Building on the call in the recent biodefense-focused BAA from NIAID for diagnostic applications, JPIAMR is also looking for diagnostic applications (7 Mar deadline). Very interesting 2 Mar 2023 Duke-Margolis webinar entitled “Data Capture
Dear All, Three things today… First, there is a newly announced hearing by the House Energy and Commerce at 9AM on this Friday, 28 April entitled “Antimicrobial Resistance: Examining an Emerging Public Health Threat.” Go here for details including a link for a livestream of hearing. It’s exciting to see this coming up … hopefully, it